FIELD: biotechnology.
SUBSTANCE: method comprises intranasal or inhalational administration of an effective amount of agent comprising a mixture of siRNA molecules that suppress gene IL-13 and IL-4 expression.
EFFECT: invention improves the efficiency of allergic asthma treatment.
2 cl, 11 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
COMPOSITION FOR INTERLEUKINE-4 CYTOKINE GENE SILENCING | 2014 |
|
RU2563989C1 |
COMPOSITION INHIBITING EXPRESSION OF INTERLEUKIN-4 AND INTERLEUKIN-13 GENES FOR THERAPY OF ALLERGIC RHINITIS | 2018 |
|
RU2710895C1 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
HUMANIZED SINGLE-DOMAIN ANTIBODY TO IL-4Rα AND ITS USE | 2021 |
|
RU2816867C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ATTENUATED Streptococcus pneumoniae STRAINS, AND ITS APPLICATION | 2018 |
|
RU2772131C2 |
COMPOSITION FOR ASTHMA PREVENTION OR TREATMENT CONTAINING MONOACETHYLDIACYL GLYCERINE COMPOUND AS ACTIVE INGREDIENT | 2014 |
|
RU2636615C2 |
COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA | 2009 |
|
RU2607569C2 |
AGENT FOR INHIBITION OF REPLICATION OF SARS-COV-2 VIRUS MEDIATED BY RNA INTERFERENCE | 2020 |
|
RU2733361C1 |
PROBIOTIC STRAIN OF Bifidobacterium longum, COMPOSITION CONTAINING SUCH STRAIN AND USE THEREOF | 2008 |
|
RU2473681C2 |
Authors
Dates
2017-04-04—Published
2016-01-28—Filed